Are DPP‑4 inhibitors safe to continue before anesthesia, and what contraindications should be considered?

DPP-4 Inhibitors Are Safe to Continue Before Anesthesia

DPP-4 inhibitors do not need to be discontinued before anesthesia and can be safely continued throughout the perioperative period, unlike GLP-1 receptor agonists which require withholding. 1, 2

Key Distinction from GLP-1 Receptor Agonists

The critical perioperative concern with incretin-based therapies relates specifically to GLP-1 receptor agonists, not DPP-4 inhibitors. GLP-1 RAs delay gastric emptying and increase aspiration risk, requiring cessation for at least three half-lives before elective surgery 3. In contrast, DPP-4 inhibitors work by preventing incretin breakdown rather than directly activating GLP-1 receptors, and they do not significantly delay gastric emptying 1.

Evidence Supporting Continuation

For select patients with type 2 diabetes and well-controlled glycemia (HbA1c <7.5%, blood glucose <180 mg/dL), DPP-4 inhibitors can be continued perioperatively 2. Multiple guidelines support this approach:

• The 2025 ADA Standards of Care classify DPP-4 inhibitors as having "neutral" effects on cardiovascular outcomes with no specific perioperative contraindications 1
• The 2022 Endocrine Society guideline found that DPP-4 inhibitors may reduce hypoglycemia risk compared to basal-bolus insulin in hospitalized patients 2, 4
• Studies demonstrate DPP-4 inhibitors combined with low-dose basal insulin are similarly effective to basal-bolus insulin with less hypoglycemia and treatment burden 4

Specific Perioperative Management

Morning of surgery approach:

• Minor or ambulatory surgery: Continue DPP-4 inhibitors 5
• Major surgery: Hold the morning dose but can resume once oral intake resumes 5

Renal dosing considerations are essential:

• Sitagliptin, saxagliptin, alogliptin, and vildagliptin require dose adjustment for renal dysfunction 6
• Linagliptin requires no dose adjustment regardless of kidney or liver function 6

Safety Profile

DPP-4 inhibitors have minimal hypoglycemia risk when used alone 7, 1. However, when combined with sulfonylureas, hypoglycemia risk increases by 50% 7. The glucose-dependent mechanism of insulin secretion makes them inherently safer during fasting states compared to sulfonylureas or insulin.

Cardiovascular safety has been established through multiple outcome trials showing neutral effects (sitagliptin, saxagliptin, alogliptin) 7, 1. Saxagliptin showed increased heart failure hospitalization risk, but this does not constitute a perioperative contraindication 7.

Common Pitfalls to Avoid

1. Do not confuse DPP-4 inhibitors with GLP-1 receptor agonists - they have fundamentally different perioperative implications
2. Do not discontinue DPP-4 inhibitors days before surgery - this is unnecessary and may worsen glycemic control
3. Do not forget renal dose adjustments - most DPP-4 inhibitors (except linagliptin) require adjustment in kidney disease 1, 6
4. Do not rely on DPP-4 inhibitors alone for severe hyperglycemia - patients with persistent glucose >180 mg/dL should receive scheduled insulin therapy 2

When to Switch to Insulin

If patients develop persistently elevated blood glucose (>180 mg/dL) on DPP-4 inhibitor therapy perioperatively, transition to scheduled insulin therapy 2. This recommendation applies to type 2 diabetes but not type 1 diabetes or other insulin-dependent forms.

Absolute Contraindications

There are no specific anesthesia-related contraindications to DPP-4 inhibitors. The standard contraindications remain:

• Active pancreatitis (discontinue if suspected) 1
• Severe allergic reactions to the specific agent 1